POLPHARMA S.
POLPHARMA S.A., a prominent player in the pharmaceutical industry, is headquartered in Poland (PL) and operates extensively across Central and Eastern Europe. Founded in 1935, the company has established itself as a leader in the development, manufacturing, and distribution of a wide range of pharmaceutical products, including prescription medications and over-the-counter solutions. With a strong focus on innovation, POLPHARMA is renowned for its commitment to quality and patient care, offering unique formulations that address various health needs. The company has achieved significant milestones, including expanding its product portfolio and enhancing its market presence through strategic partnerships. As a result, POLPHARMA has solidified its position as a trusted name in the pharmaceutical sector, recognised for its dedication to improving health outcomes across the region.
DitchCarbon Score
How does POLPHARMA S.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
POLPHARMA S.'s score of 0 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
POLPHARMA S.'s reported carbon emissions
In 2022, POLPHARMA S. reported total carbon emissions of approximately 175,880 kg CO2e, which includes 39,710 kg CO2e from Scope 1 emissions and 175,880 kg CO2e from Scope 2 emissions. The Scope 3 emissions, primarily from employee commuting, accounted for about 78,340 kg CO2e. Comparatively, in 2021, the total emissions were about 214,650 kg CO2e, indicating a reduction in emissions in 2022. The breakdown for 2021 included 6,460 kg CO2e from Scope 1 and 188,390 kg CO2e from Scope 2. Despite these figures, POLPHARMA S. has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company is actively working within the pharmaceutical industry context, which is increasingly focused on reducing carbon footprints and enhancing sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | |
|---|---|
| Scope 1 | 39,710 |
| Scope 2 | 175,880 |
| Scope 3 | 78,340 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
POLPHARMA S. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
